How should chronic kidney disease be managed?

Management of Chronic Kidney Disease

Manage CKD with a comprehensive, evidence-based strategy centered on four pharmacologic pillars—SGLT2 inhibitors, ACE inhibitors or ARBs, blood pressure optimization, and statin therapy—combined with lifestyle modification, regular monitoring, and timely nephrology referral to reduce cardiovascular events, slow progression to kidney failure, and improve quality of life.

Initial Assessment and Staging

Diagnosis and staging require simultaneous measurement of both eGFR and urine albumin-to-creatinine ratio (UACR), as this dual assessment accurately stratifies risk and guides treatment intensity. 1, 2

• eGFR categories:

  • G1: ≥90 mL/min/1.73 m² (normal/high) 2
  • G2: 60–89 mL/min/1.73 m² (mildly decreased) 2
  • G3a: 45–59 mL/min/1.73 m² (mild-moderate) 2
  • G3b: 30–44 mL/min/1.73 m² (moderate-severe) 2
  • G4: 15–29 mL/min/1.73 m² (severe) 2
  • G5: <15 mL/min/1.73 m² (kidney failure) 2

• Albuminuria categories:

  • A1: <30 mg/g (normal-mild) 2
  • A2: 30–300 mg/g (moderate) 2
  • A3: >300 mg/g (severe) 2

• Use creatinine-based eGFR initially; when cystatin C is available, use combined creatinine-cystatin C equations for greater accuracy. 1, 2, 3

• Confirm chronicity by repeating abnormal eGFR or UACR after ≥3 months, or by reviewing prior labs, imaging showing reduced kidney size, or pathology demonstrating fibrosis. 1, 2

Pharmacologic Management

SGLT2 Inhibitors (First-Line Therapy)

SGLT2 inhibitors are the cornerstone of modern CKD management and should be initiated in all eligible patients to reduce cardiovascular events and slow progression. 1, 2, 4

• Initiate SGLT2 inhibitors (Grade 1A) for:

  • All adults with type 2 diabetes and eGFR ≥20 mL/min/1.73 m² 1, 2, 4
  • All adults with eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g, regardless of diabetes status 2, 4
  • All adults with eGFR ≥20 mL/min/1.73 m² and heart failure, regardless of diabetes status 2, 4

• Consider SGLT2 inhibitors (Grade 2B) for:

  • Adults with eGFR 20–45 mL/min/1.73 m² and UACR <200 mg/g 2, 4

• Continue SGLT2 inhibitors even when eGFR falls below 20 mL/min/1.73 m² unless the patient is intolerant or initiates kidney replacement therapy. 2

• Withhold during prolonged fasting, surgery, or critical illness due to ketoacidosis risk. 2

• A modest, reversible eGFR dip after initiation is expected and hemodynamic; do not discontinue therapy for this reason. 2

ACE Inhibitors or ARBs (Renin-Angiotensin System Blockade)

ACE inhibitors or ARBs at maximum tolerated dose are mandatory for all patients with severe albuminuria (A3, >300 mg/g) and strongly recommended for moderate albuminuria (A2, 30–300 mg/g). 1, 2, 4

• Prescribe ACE-I or ARB for UACR 30–299 mg/g (Grade 1B). 1
• Strongly prescribe ACE-I or ARB for UACR ≥300 mg/g and/or eGFR <60 mL/min/1.73 m² (Grade 1A). 1, 2, 4
• Continue ACE-I/ARB even when eGFR declines below 30 mL/min/1.73 m². 2
• Check blood pressure, serum creatinine, and potassium 2–4 weeks after initiation or dose escalation. 2
• Discontinue only if serum creatinine rises >30% within 4 weeks of initiation or dose increase. 2
• Manage hyperkalemia with dietary restriction, diuretics, or potassium binders before stopping ACE-I/ARB. 2
• Do not combine ACE inhibitors with ARBs; evidence does not support dual RAAS blockade. 5

Blood Pressure Targets

Blood pressure control is critical to slow CKD progression and reduce cardiovascular risk. 1, 2

• Target BP ≤130/80 mmHg for patients with albuminuria ≥30 mg/24 hours (Grade 2D). 1, 2, 4
• Target BP ≤140/90 mmHg for patients with albuminuria <30 mg/24 hours (Grade 1B). 1, 2, 4
• Some guidelines recommend systolic BP <120 mmHg for most CKD patients when tolerated. 4
• Optimize blood pressure control and reduce blood pressure variability to slow progression. 1

Nonsteroidal Mineralocorticoid Receptor Antagonists (Finerenone)

Add finerenone for patients with type 2 diabetes, persistent albuminuria despite maximally tolerated ACE-I/ARB, eGFR >25 mL/min/1.73 m², and normal potassium (Grade 2A). 1, 2, 4

• Dosing: 10 mg daily if eGFR 25–59 mL/min/1.73 m²; 20 mg daily if eGFR ≥60 mL/min/1.73 m², provided serum potassium ≤4.8 mmol/L. 2
• Hold finerenone if potassium >5.5 mmol/L; continue with close monitoring when potassium is 4.9–5.5 mmol/L. 2
• Monitor potassium at 1 month after initiation, then every 4 months. 2
• Finerenone can be co-administered with ACE-I/ARB and SGLT2 inhibitors. 2

GLP-1 Receptor Agonists

Add a long-acting GLP-1 receptor agonist for adults with type 2 diabetes and CKD who have not reached glycemic targets despite metformin and SGLT2 inhibitors, selecting agents with proven cardiovascular benefit (Grade 1B). 1, 2

Statin Therapy for Cardiovascular Risk Reduction

All CKD patients are at elevated cardiovascular risk and require statin therapy. 2, 4, 6

• Age ≥50 years with eGFR <60 mL/min/1.73 m² (G3a–G5): prescribe a statin or statin + ezetimibe (Grade 1A). 2, 4
• Age ≥50 years with eGFR ≥60 mL/min/1.73 m² (G1–G2): prescribe a statin (Grade 1B). 2
• Age 18–49 years with coronary disease, diabetes, prior stroke, or 10-year ASCVD risk >10%: prescribe a statin (Grade 2A). 2
• Low-dose aspirin is advised for secondary prevention in CKD patients with established ischemic cardiovascular disease (Grade 1C). 2

Lifestyle Interventions

Lifestyle modification is essential to slow CKD progression and reduce cardiovascular risk. 1, 2

• Reduce dietary sodium to <2 g per day. 2, 4
• Limit dietary protein intake to 0.8 g/kg body weight per day for nondialysis-dependent stage 3 or higher CKD (Grade 1A). 1, 2
• Undertake moderate-intensity physical activity for ≥150 minutes per week or to a level compatible with cardiovascular and physical tolerance (Grade 1D). 1, 2
• Avoid sedentary behavior. 1
• Achieve smoking cessation. 1, 2
• Aim for a body mass index of 20–25 kg/m². 2
• Target HbA1c of approximately 7% in diabetic patients. 2, 4
• Adopt a plant-based Mediterranean-style diet to lower cardiovascular risk. 1, 2

Monitoring and Surveillance

Monitoring frequency should be risk-adjusted based on eGFR category and albuminuria level. 2, 4

• CKD G1–G2 (eGFR ≥60 mL/min/1.73 m²): assess eGFR and UACR annually. 2
• CKD G3a (eGFR 45–59 mL/min/1.73 m²): assess 1–2 times per year. 2
• CKD G3b (eGFR 30–44 mL/min/1.73 m²): assess 2–3 times per year. 2
• CKD G4 (eGFR 15–29 mL/min/1.73 m²): assess 3–4 times per year. 2
• Monitor for complications including anemia, bone-mineral disorders (calcium, phosphorus, parathyroid hormone), metabolic acidosis (treat when bicarbonate <18 mmol/L), and hyperkalemia. 2, 6
• Periodically monitor serum creatinine and potassium when ACE inhibitors, ARBs, or diuretics are used. 1

Nephrology Referral

Timely nephrology referral is critical for high-risk patients to optimize outcomes and prepare for kidney replacement therapy. 2, 6, 3

• Refer when 5-year kidney failure risk is 3–5%, or when eGFR <30 mL/min/1.73 m² or albuminuria ≥300 mg/24 hours. 2, 5
• Use externally validated risk equations to estimate absolute risk of kidney failure. 1, 2
• A 2-year kidney failure risk >10% triggers multidisciplinary care initiation. 1, 2, 5
• A 2-year kidney failure risk >40% determines timing of modality education, vascular access planning, or transplant referral. 1, 2

Medication Safety and Dose Adjustment

All renally cleared medications must have doses adjusted according to eGFR to prevent toxicity. 2, 6

• Avoid NSAIDs in all CKD patients due to high nephrotoxicity risk and potential for precipitating acute kidney injury. 5, 4, 6
• Review and limit over-the-counter medicines and herbal remedies that may be harmful. 5
• Use therapeutic drug monitoring for drugs with narrow therapeutic windows (e.g., aminoglycosides). 5
• Avoid iodinated contrast when possible in patients with eGFR <30 mL/min/1.73 m² due to contrast-induced nephropathy risk. 5
• After temporary interruption of ACE-I/ARB or SGLT2 inhibitors for surgery or acute illness, restart these agents promptly to avoid unintended harm. 2

Critical Pitfalls and Caveats

Do not discontinue ACE-I/ARB solely because eGFR falls below 30 mL/min/1.73 m²; continue unless specific contraindications arise. 2

• Hyperkalemia should be managed medically before stopping ACE-I/ARB. 2
• A rise in serum creatinine up to 30% within 4 weeks after ACE-I/ARB initiation is acceptable; discontinue only if the rise exceeds 30%. 2
• The initial eGFR dip after starting SGLT2 inhibitors is hemodynamic and reversible; it should not prompt drug cessation. 2
• Withhold SGLT2 inhibitors during prolonged fasting, surgery, or critical illness to avoid ketoacidosis. 2
• Progression should not be diagnosed on minor eGFR changes that merely cross category thresholds; both a category shift and ≥25% decline are required. 2
• A single abnormal eGFR or albuminuria result may reflect acute kidney injury; confirm chronicity with repeat testing or historical data. 1, 2
• All CKD patients have heightened acute kidney injury risk and need vigilant monitoring during intercurrent illness, contrast exposure, or nephrotoxic medication use. 2, 5
• Do not withhold appropriate diagnostic imaging due to unfounded contrast concerns in patients with moderate CKD. 5